Inoviem Scientific is a Bioanalytical R&D company established in 2011 in Strasburg – France.

Inoviem scientific team works closely with big pharma, biotechs, and public and private research institutions in target deconvolution, clinical mechanism of action elucidation, GPCRs and membranous protein identification, biomarker identification and patient stratification. Inoviem Scientific has pioneered translational pharmacology from bench to bed – and return. Our mission is clear: to get the right treatment to the right patients within the right therapeutic window.

We worked on more than 200 discovery, preclinical and clinical studies in almost any therapeutic areas including: Oncology, Inflammatory, Autoimmune, Fibrosis, Respiratory, Metabolic, Neurodegeneration and CNS-related disorders.  

Inoviem is headquartered in Strasbourg Bioparc and has more 800m2 of laboratories fully equipped with latest bioanalytical technologies and platforms, including BSL2 Labs, LC-MS/MS, SPR, and Immunoenzymatic platforms.